{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T22:15:15Z","timestamp":1791152115496,"version":"4.1.0"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:p>PURPOSE: To evaluate salvage treatment outcome of patients with relapsed Hodgkin\u2019s disease (HD) and to distinguish different risk groups using identified prognostic factors.<\/jats:p>\n          <jats:p>PATIENTS AND METHODS: From 4,754 patients registered in the German Hodgkin\u2019s Lymphoma Study Group (GHSG) database between 1988 and 1999, 422 patients with early (n = 170) or late (n = 252) relapsed HD were identified. One hundred seven patients (25%) relapsed after radiotherapy (RT) for early stages, 133 patients (32%) after combined-modality therapy for intermediate stages, and 182 patients (43%) after chemotherapy (CT) and RT to initial bulky disease or residual lymphoma for advanced stages. At relapse, characteristics of these 422 patients (median age, 38 years; range, 17 to 77) were stage III\/IV, 45%; B symptoms, 24%; elevated erythrocyte sedimentation rate, 29%; anemia, 13%; and Karnofsky performance score, less than 90 in 13%. At first relapse, salvage treatment was RT in 13%, CT in 54%, and high-dose chemotherapy (HDCT) with autologous stem-cell transplantation (ASCT) in 33%.<\/jats:p>\n          <jats:p>RESULTS: Median follow-up time after relapse was 45 months. Freedom from second failure (FF2F) and overall survival (OS) were 81% and 89% for relapse after RT, 33% and 46% for early relapse after CT, and 43% and 71% for late relapse after CT, respectively. In multivariate analysis, independent risk factors were time to relapse, clinical stage at relapse, and anemia at relapse. Four subgroups with significantly different FF2F and OS were identified. The prognostic score was predictive for patients who relapsed after RT, CT with conventional CT salvage, and CT with HDCT\/ASCT.<\/jats:p>\n          <jats:p>CONCLUSION: In the GHSG database, time to relapse and clinical stage and anemia at relapse are relevant factors and can be used to form a prognostic score for HD patients at relapse.<\/jats:p>","DOI":"10.1200\/jco.2002.20.1.221","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T00:38:26Z","timestamp":1487896706000},"page":"221-230","source":"Crossref","is-referenced-by-count":21,"title":["New Prognostic Score Based on Treatment Outcome of Patients With Relapsed Hodgkin\u2019s Lymphoma Registered in the Database of the German Hodgkin\u2019s Lymphoma Study Group"],"prefix":"10.1200","volume":"20","author":[{"given":"Andreas","family":"Josting","sequence":"first","affiliation":[{"name":"From the First Department of Internal Medicine, University Hospital Cologne, and German Hodgkin\u2019s Lymphoma Study Group, Cologne; Medizinische Universita\u0308tsklinik Mu\u0308nster, Medizinische Klinik A, Mu\u0308nster; Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Klinikum Gro\u03b2hadern, Medizinische Klinik III, Munich; Klinikum der Albert-Ludwig-Universita\u0308t Freiburg, Innere Medizin I, Freiburg; and Carl-Thiem-Klinikum Cottbus, II Medizinische Klinik, Cottbus, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Franklin","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, University Hospital Cologne, and German Hodgkin\u2019s Lymphoma Study Group, Cologne; Medizinische Universita\u0308tsklinik Mu\u0308nster, Medizinische Klinik A, Mu\u0308nster; Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Klinikum Gro\u03b2hadern, Medizinische Klinik III, Munich; Klinikum der Albert-Ludwig-Universita\u0308t Freiburg, Innere Medizin I, Freiburg; and Carl-Thiem-Klinikum Cottbus, II Medizinische Klinik, Cottbus, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"May","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, University Hospital Cologne, and German Hodgkin\u2019s Lymphoma Study Group, Cologne; Medizinische Universita\u0308tsklinik Mu\u0308nster, Medizinische Klinik A, Mu\u0308nster; Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Klinikum Gro\u03b2hadern, Medizinische Klinik III, Munich; Klinikum der Albert-Ludwig-Universita\u0308t Freiburg, Innere Medizin I, Freiburg; and Carl-Thiem-Klinikum Cottbus, II Medizinische Klinik, Cottbus, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Koch","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, University Hospital Cologne, and German Hodgkin\u2019s Lymphoma Study Group, Cologne; Medizinische Universita\u0308tsklinik Mu\u0308nster, Medizinische Klinik A, Mu\u0308nster; Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Klinikum Gro\u03b2hadern, Medizinische Klinik III, Munich; Klinikum der Albert-Ludwig-Universita\u0308t Freiburg, Innere Medizin I, Freiburg; and Carl-Thiem-Klinikum Cottbus, II Medizinische Klinik, Cottbus, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Beykirch","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, University Hospital Cologne, and German Hodgkin\u2019s Lymphoma Study Group, Cologne; Medizinische Universita\u0308tsklinik Mu\u0308nster, Medizinische Klinik A, Mu\u0308nster; Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Klinikum Gro\u03b2hadern, Medizinische Klinik III, Munich; Klinikum der Albert-Ludwig-Universita\u0308t Freiburg, Innere Medizin I, Freiburg; and Carl-Thiem-Klinikum Cottbus, II Medizinische Klinik, Cottbus, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Heinz","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, University Hospital Cologne, and German Hodgkin\u2019s Lymphoma Study Group, Cologne; Medizinische Universita\u0308tsklinik Mu\u0308nster, Medizinische Klinik A, Mu\u0308nster; Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Klinikum Gro\u03b2hadern, Medizinische Klinik III, Munich; Klinikum der Albert-Ludwig-Universita\u0308t Freiburg, Innere Medizin I, Freiburg; and Carl-Thiem-Klinikum Cottbus, II Medizinische Klinik, Cottbus, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rudolph","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, University Hospital Cologne, and German Hodgkin\u2019s Lymphoma Study Group, Cologne; Medizinische Universita\u0308tsklinik Mu\u0308nster, Medizinische Klinik A, Mu\u0308nster; Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Klinikum Gro\u03b2hadern, Medizinische Klinik III, Munich; Klinikum der Albert-Ludwig-Universita\u0308t Freiburg, Innere Medizin I, Freiburg; and Carl-Thiem-Klinikum Cottbus, II Medizinische Klinik, Cottbus, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Diehl","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, University Hospital Cologne, and German Hodgkin\u2019s Lymphoma Study Group, Cologne; Medizinische Universita\u0308tsklinik Mu\u0308nster, Medizinische Klinik A, Mu\u0308nster; Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Klinikum Gro\u03b2hadern, Medizinische Klinik III, Munich; Klinikum der Albert-Ludwig-Universita\u0308t Freiburg, Innere Medizin I, Freiburg; and Carl-Thiem-Klinikum Cottbus, II Medizinische Klinik, Cottbus, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"From the First Department of Internal Medicine, University Hospital Cologne, and German Hodgkin\u2019s Lymphoma Study Group, Cologne; Medizinische Universita\u0308tsklinik Mu\u0308nster, Medizinische Klinik A, Mu\u0308nster; Ludwig-Maximilians-Universita\u0308t Mu\u0308nchen, Klinikum Gro\u03b2hadern, Medizinische Klinik III, Munich; Klinikum der Albert-Ludwig-Universita\u0308t Freiburg, Innere Medizin I, Freiburg; and Carl-Thiem-Klinikum Cottbus, II Medizinische Klinik, Cottbus, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211193272102"},{"key":"e_1_3_2_2_2","first-page":"13a,","volume":"16","year":"1997","unstructured":"Carde P, Noordijk E, Hagenbeek A, et al: Superiority of EBVP chemotherapy in combination with involved field irradiation (EBVP\/IF) over subtotal nodal irradiation (STNI) in favorable clinical stage (CS) I-II Hodgkin\u2019s disease: The EORTC-GPMC H7F randomized trial. Proc Am Soc Clin Oncol 16:: 13a,,1997 (abstr 44)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1638"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/9.suppl_5.S91"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90353-0"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(96)00518-7"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930415)71:8<2613::AID-CNCR2820710828>3.0.CO;2-T"},{"key":"e_1_3_2_8_2","first-page":"737a,","volume":"94","year":"1999","unstructured":"Josting A, Mapara M, Reiser M, et al: A dose-intensified therapy (DIT) prior to HDCT\/ASCT in patients with relapsed and refractory lymphoma. Blood 94:: 737a,,1999 (suppl 1)","journal-title":"Blood"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008343823292"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2817"},{"key":"e_1_3_2_11_2","unstructured":"Rueffer U Sieber M Tesch H: Final results of a randomized trial (HD4): 30 Gy extended field plus 10 Gy involved field radiation is equally effective to 40 Gy extended field radiation in patients with Hodgkin\u2019s disease PS I\/II. Blood 90:1431a 997 (suppl 1)"},{"key":"e_1_3_2_12_2","first-page":"2113a,","volume":"94","year":"1999","unstructured":"Tesch H, Sieber M, Rueffer U, et al: Second interim analysis of the HD7 trial of the GHSG: 2 cycles ABVD plus extended field radio-therapy is more effective than radiotherapy alone in early stage HD. Blood 94:: 2113a,,1999","journal-title":"Blood"},{"key":"e_1_3_2_13_2","first-page":"586a,","volume":"90","year":"1997","unstructured":"Sieber M, Rueffer U, Tesch H, et al: Rapidly alternating COPP + ABV + IMEP (CAI) is equally effective as alternating COPP + ABVD (CA) for Hodgkin\u2019s disease: Final results of two randomized trials for intermediate (HD5 protocol) and advanced (HD6 protocol) stages. Blood 90:: 586a,,1997","journal-title":"Blood"},{"key":"e_1_3_2_14_2","first-page":"2580a,","volume":"92","year":"1998","unstructured":"Rueffer U, Sieber M, Pfistner B, et al: Reduction of radiotherapy volume in intermediate Hodgkin\u2018s disease: Interim analysis of a randomized trial in patients CS I\/II of the GHSG. Blood 92:: 2580a,,1998","journal-title":"Blood"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3810"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392104"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.4.623"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058072"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058662"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.2.451.bloodjournal862451"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008283909959"},{"key":"e_1_3_2_23_2","first-page":"801","volume":"89","year":"1991","unstructured":"Horning SJ, Chao NJ, Negrin RS, et al: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin\u2018s disease: Analysis of the Stanford University results and prognostic indices. Blood 89:: 801,1991-813,","journal-title":"Blood"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_3_2_25_2","first-page":"2a,","volume":"18","year":"1999","unstructured":"Schmitz N, Sextro M, Pfistner B, et al: High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin\u2018s disease (HD): Final results of a randomized GHSG and EBMT trial (HD-R1). Proc Am Soc Clin Oncol 18:: 2a,,1999 (abstr 5)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.4.1280"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.332"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.210"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.10.2292.2292"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059242"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960915)78:6<1293::AID-CNCR18>3.0.CO;2-W"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.20.1.221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T17:13:15Z","timestamp":1727629995000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.20.1.221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1200\/JCO.2002.20.1.221"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.20.1.221","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}